SEARCH

SEARCH BY CITATION

This article includes supplementary materials available via the Internet at http://www.interscience.wiley.com/jpages/0364-5134/suppmat

FilenameFormatSizeDescription
ana21363-supplementaryfigure.eps2114KSupplementary Figure. Median Counts per mm 3for total CD19+ B Cells (A), CD19+CD27+ Memory B Cells (B), and CD19+CD27- Naive B Cells (C). As expected from its mechanism of action, treatment with rituximab led to rapid depletion of peripheral B cells (measured by CD19 expression), which was near-complete (99.8%) by Week 2, and sustained through Week 48, with reconstitution to mean 34.5% of baseline by Week 72. The majority of reconstituting cells were CD19+CD27- naive B cells (mean 51% of baseline) rather than CD19+CD27+ memory B cells (mean 14% of baseline).
ana21363-SupplementaryTable1.pdf99KSupplementary Table 1: Patient Baseline Characteristics at Entry (ITT Population).
ana21363-SupplementaryTable2.pdf49KSupplementary Table 2. Adverse Events, N (%).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.